The nomination committee of Sedana Medical, which in relation to the annual general meeting 2020 consists of Karl Tobieson (chairman of the nomination committee and appointed by Linc AB), Thomas Eklund (chairman of the board), Sten Gibeck (shareholder and board member) and Anders Walldow (shareholder, directly and indirectly through Brohuvudet AB), has presented the following resolution proposals for the general meeting.

- The nomination committee proposes that the chairman of the board, Thomas Eklund, is elected as chairman of the general meeting.

- The nomination committee proposes that the board of directors, which currently consist of five ordinary members without deputy board members, shall consist of six ordinary board members without deputy board members, and that a registered audit company shall be appointed as auditor.

- The nomination committee proposes re-election of the current board members Thomas Eklund (chairman), Sten Gibeck, Bengt Julander, Ola Magnusson and Eva Walde, and election of Christoffer Rosenblad as new ordinary board member. The nomination committee further proposes re-election of Thomas Eklund as chairman of the board.

- The nomination committee proposes election of PricewaterhouseCoopers AB as new auditor for the period until the end of the next annual general meeting. PricewaterhouseCoopers AB has informed that Leonard Daun will be appointed as principal auditor.

- The nomination committee proposes that fees payable to the board of directors shall amount to a total of SEK 1,000,000 for the period until the end of the next annual general meeting, whereby SEK 400,000 shall be paid to the chairman of the board, SEK 100,000 shall be paid to each of the proposed board members Sten Gibeck, Bengt Julander and Ola Magnusson (who are also major shareholders in the company) and SEK 150,000 shall be paid to each of the other board members. It is further proposed that fees payable for work in the board's audit committee, which is under establishment, shall be paid with SEK 25,000 to the chairman of the audit committee and with SEK 12,500 to each of the other members, and that fees payable to the auditor shall be paid in accordance with approved invoices within the frame of the quotation.

Christoffer Rosenblad, who is proposed as new ordinary board member of Sedana Medical, has long and broad experience mainly within medical technology. Christoffer is CFO and deputy CEO of XVIVO Perfusion AB and has previously held several leading positions within business and strategical management at Novartis and LG Electronics. Christoffer is a member of the board of a subsidiary within the XVIVO Perfusion group but does not hold any other board positions.  Christoffer has a Master of Science in Mechanical Engineering from the Chalmers University of Technology and a Bachelor of Science in Financial Economy from the School of Business, Economics and Law at the University of Gothenburg in Sweden.

Information about the other proposed board members is available on www.sedanamedical.com.

The annual general meeting in Sedana Medical will be held Tuesday 19 May 2020 at 4:00 p.m. (CEST) in Stockholm. The nomination committee's resolution proposals will also be presented in the notice to attend the annual general meeting. 

For additional information, please contact:
Karl Tobieson, Chairman of the nomination committee
Mobile: +46 70 935 85 74
E-mail: karl.tobieson@medcap.se
             

Thomas Eklund, Chairman of the Board
Mobile: +46 70 824 20 25
E-mail: thomas.eklund@investorab.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

The information was released for public disclosure, through the agency of the contact person above, on April 9, 2020 at 9:00 p.m. (CET).

About Sedana Medical

Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major pivotal study is currently ongoing to obtain market approval in Europe for inhaled sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane). The company expects the registration of IsoConDa in Europe to take place during the second half of 2021. Three years thereafter Sedana Medical expects sales of SEK 500 million in Europe and an EBITDA margin of about 40 percent.

The market for Sedana Medical's sedation therapy of AnaConDa and IsoConDa consists primarily of sedation of mechanically ventilated intensive care patients. Today, these patients are sedated intravenously which leads to several challenges for both patients and care givers. Challenges that are solved by inhaled sedation. Based on an estimate of seven to eight million patients being sedated in intensive care due to mechanical ventilation globally, on average three to four days, Sedana Medical estimates the total market potential to SEK 20-30 billion, evenly distributed between the US, Europe and Asia. The company has initiated a process to obtain market approval in the US in 2024. Registration activities are also initiated in other markets outside the EU.

Sedana Medical has direct sales in the Nordic countries, Germany, Benelux, France, Great Britain and Spain as well as external distributors in parts of the rest of Europe, Australia, Canada, China, India, Israel, Japan, Mexico and South Korea. The company was founded in 2005 and is headquartered in Stockholm, Sweden, with medical device development in Ireland.